找不到产品?留下需求帮您找
一键询价UPCISCC090 人舌头鳞癌细胞 QCH766
一周
3500¥
KNS62 人肺支气管鳞状细胞癌 QCH767
一周
3500¥
HCC95 人肺腺癌细胞 QCH768
一周
3500¥
HARA 人肺腺癌细胞 QCH769
一周
3500¥
EPLC272H 人肺腺癌细胞 QCH770
一周
4000¥
NCI-H810 人非小细胞肺癌细胞 QCH771
一周
5000¥
HBL-1 人弥漫性大B细胞淋巴瘤 QCH772
一周
1800¥
FTC238 人滤泡状甲状腺癌细胞,肺转移 XY-H773
一周
3500¥
SNU-719 人胃癌细胞 QCH774
一周
3500¥
BT549+GFP+LUC 人乳腺癌细胞 QCH766GL
钦诚生物 | 一周
4500¥
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:Nilutamide 产品别名:见爱必信官网 英文别名:Nilutamide 靶点:Androgen Receptor CAS:63612-50-0 纯度:>98% 外观:见爱必信官网 保存方法:-20°C 描述: Nilutamide (Nilandron, Anandron, RU 23908) is an androgen receptor (AR) blocker with an IC50 of 0.4 μM. The twofold stimulation of Shionogi cell proliferation caused by a 10-day exposure to 1 nM testosterone is competitively reversed by incubation with Nilutamide, at the IC50. Nilutamide at the IC50 values of 87 nM and in T-47D and ZR-75-1 cells blocks the marked increase in GCDFP-15 release induced by 1 nM testosterone.Nilutamide blocks the androgen induction of CYP27A1. Treatment of the HepG2 cells with dihydrotestosterone in presence of the AR antagonist Nilutamide almost completely abolishes the dihydrotestosterone-induced effect on the CYP27A1 promoter activity. Incubation with 100 μg/mL Nilutamide results in decreased movement of S. mansoni adults. Nilutamide inhibits hepatic cytochrome P-450 activity. Total worm burden reductions of 5.1%–35.6% are achieved with Nilutamide. The highest female worm burden reduction of 75.4% is observed with a 200 mg/kg dose of Nilutamide, while moderate female worm burden reductions of 22.5%–27.5% are observed following 50 mg/kg, 100 mg/kg and 400 mg/kg Nilutamide doses. At 400 mg/kg, Nilutamide reduced total and female worm burdens by 84.8% and 71.3%, respectively. Combinations of Nilutamide (100 mg/kg) and praziquantel (50 mg/kg or 100 mg/kg) reveals an increase in worm survival, above the level observed with praziquantel or Nilutamide monotherapy. However, a combination of Nilutamide (200 mg/kg) and praziquantel (100 mg/kg) produces statistically significant total and female worm burden reductions by 90.6% and 85.1%, respectively. Anandron (20 mg/kg/day) with even low doses of buserelin leads to an immediate decrease in prostate weight that is complete at 15 days. Nilutamide and Dasatinib has entered in a phase II clinical trial in the treatment of prostate cancer. Nilutamide plus bicalutamide, buserelin, cyproterone acetate, flutamide, goserelin or leuprolide acetate has entered in a phase III clinical trial in the treatme 溶解性:DMSO :10 mM 体外研究: 体内研究:
产品信息订购:
|